AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Kairos Pharma, Ltd.
XASE · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01JLR1S38
0.56▲ 0.01 (2.67%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.54
Day's Range
0.53 – 0.59
52-Week Range
0.22 – 2.16
Volume
108.1K
Avg Volume
678.5K
Share Statistics
Shares Outstanding
Employees
1
Exchange
XASE
Listed
2024-09-16
Share count as of August 12, 2026

Kairos Pharma, Ltd. (KAPA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Kairos Pharma, Ltd. (KAPA)
What is Kairos Pharma, Ltd.'s Market Cap?
Kairos Pharma, Ltd.'s Market Cap is $13.2M, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Enterprise Value?
Kairos Pharma, Ltd.'s Enterprise Value is $10.6M, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s EV / EBITDA?
Kairos Pharma, Ltd.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Revenue (TTM)?
Kairos Pharma, Ltd.'s Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Net Income (TTM)?
Kairos Pharma, Ltd.'s Net Income (TTM) is -$5.8M, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s EBITDA?
Kairos Pharma, Ltd.'s EBITDA is -$5.8M, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Diluted EPS (TTM)?
Kairos Pharma, Ltd.'s Diluted EPS (TTM) is -0.24, based on as-reported figures from SEC (XBRL) filings.
What is Kairos Pharma, Ltd.'s Net Debt?
Kairos Pharma, Ltd.'s Net Debt is -$2.6M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · KAPAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Loss from operations
Other income:
Non-Operating Income (Expense)
Total other income
NET LOSS
Earnings Per Share (Basic)
Earnings Per Share (Diluted)